Organic Active Ingredients TRIZ Cases

Cross-linked polyvinylpyrrolidone prevents rotigotine crystallization in adhesive layers, maintaining drug stability and skin permeability.

Segmented extraction with pH control and enzymes boosts glycoside yield while maintaining product stability.

Segmented aqueous formulation with permeant ions and osmolality agents improves target organ dose while managing systemic toxicity.

Specific aryl substitutions on diaza-spiro-pyridinone derivatives minimize hERG-channel interactions while maintaining MCH-1 receptor binding affinity.

Pyrazine and pyridine compounds inhibit ATR kinase activity, resolving the trade-off between treatment efficacy and healthy cell toxicity.

A stable cabazitaxel liquid formulation uses a co-solvent system to form nanodispersions under 500 nm for direct parenteral administration.

Segments immunosuppressive mechanisms by targeting CD73 and A2A receptors simultaneously, resolving modest clinical benefits from single-agent therapies.

Merging dihydroavenanthramide D with climbazole overcomes formulation complexity by achieving superior efficacy without high active compound quantities.

New compounds inhibit cytidine deaminase to improve acid stability and bioavailability of gemcitabine.

CV-8972 shifts cardiac metabolism from fatty acid to glucose oxidation.

ETV3 and ETV6 inhibitors block monocyte differentiation into dendritic cells, reducing inflammatory disorder severity.

A GIRK2 channel expression strategy restores cone light sensitivity by creating a short phototransduction cascade independent of native proteins.

Modulating specific miRNAs inhibits HER2 activation, overcoming Trastuzumab resistance and reducing toxicity.

Cyclizing intermediates to produce pyranochromenyl phenol derivatives that alleviate insulin resistance without causing obesity or inflammation.

Wearable daytime dialysis unit paired with stationary nighttime system enables continuous toxin removal while preserving patient mobility.

15-oxo-EPA and 15-oxo-DGLA derivatives reduce fibrosis and inflammation by modulating metabolic pathways, addressing persistent underlying pathologies.

Ugi reaction synthesis of cationic lipid analogues overcomes low in vivo delivery efficiency and biological toxicity inherent to conventional gene carriers.

Tailored multidentate metal complexes improve emission efficiency and stability in OLEDs by addressing poor processing ability of traditional materials.

Tulathromycin and gallic acid combine to disrupt bacterial membranes and inhibit protein synthesis, enhancing antimicrobial efficacy.

Inhibiting sortilin 1 reduces osteogenic phenotype in vascular smooth muscle cells, addressing ineffective cardiovascular therapies.

Combining deuterated ETBR antagonists with immune checkpoint inhibitors reduces tumor volume and extends survival in resistant urothelial and kidney cancers.

Combines binimetinib and copanlisib to inhibit ovarian tumor cell growth through synergistic MEK and PI3K pathway targeting.

Inhibiting SETD2 reduces pancreatic cancer cell proliferation, overcoming therapeutic resistance and relapse associated with conventional treatments.

Replacing salt with C12-18 fatty acid prevents stringiness while maintaining foam stability and high viscosity.

An anti-EGFR antibody linked to a SRC kinase inhibitor forms an immunoconjugate for targeted cancer therapy.

Proteolytic enzyme inhibitors protect peptides from gastrointestinal degradation, increasing oral bioavailability by five times.

Levo-ornidazole formulation segments racemic mixtures to isolate the active enantiomer for targeted antiparasitic therapy.

Agglomerated lactose carrier improves flowability and dispersibility of micronized JAK inhibitor particles, resolving bulk powder cohesion issues.

3,3-difluoroallylamines inhibit vascular adhesion protein-1 to reduce leukocyte infiltration and inflammatory responses in nonalcoholic hepatosteatosis.

Ullmann coupling and Grignard reactions synthesize lobaric acid analogues, resolving low yield and high cost of natural extraction.

Segmented lyophilized powder and vehicle prevent needle clogging during fast push injection of crystalline iloperidone.

Colloidal dispersion of medicament and phosphatidyl choline in propylene glycol achieves rapid absorption while suppressing cutaneous irritation.

Segmented polymer conjugates release anticancer agents at delayed intervals, achieving synergistic tumor volume reduction while minimizing systemic toxicity.

Nanopore membrane regulates drug diffusion via osmotic engine to eliminate burst release and maintain constant therapeutic levels.

A specialized essential amino acid composition stimulates muscle protein synthesis to preserve mass.

Boulton-Katritzky rearrangement converts oxadiazoles into triazoles using stable reagents.

Selective oxopicolinamide derivatives inhibit factor XIa to prevent thrombosis while reducing bleeding risks associated with traditional anticoagulants.

Non-aqueous naloxone base formulations bypass nasal mucosa damage to deliver reliable bioavailability without administration delays.

Form A resolves rapid absorbability safety concerns by maintaining active ingredient consistency through controlled ethanol-water crystallization.

A crystal form of a compound and fumaric acid with controlled particle size increases dissolution rates.

Succinic acid buffers aqueous fosfomycin to physiological pH, ensuring stability and safety without on-site mixing.

Iodination and reduction of sugar rings create deoxyglucose phenyl C-glucosides that inhibit SGLT2, avoiding liver toxicity from metformins.

Modifying imidazo[1,2-a]pyrimidine structures optimizes Toll-like receptor 7 binding affinity to resolve insufficient viral RNA recognition.

Modified oligonucleotides with GalNAc conjugates enhance stability and delivery to resolve cytotoxicity while suppressing TfR2 mRNA.

Administering CDK 4/6 inhibitors targets the DUB3-SNAIL1 pathway to prevent further metastasis in triple-negative breast cancer patients.